ADIL Adial Pharmaceuticals Inc

-0.14  -4%
Previous Close 3.97
Open 3.98
Price To Book 5.63
Market Cap 27576000
Shares 7,200,000
Volume 529,956
Short Ratio
Av. Daily Volume 1,709,428

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 European trial planned 1H 2019.
Alcohol use disorder

Latest News

  1. Four Biotech Stocks Setting The Standard On Thursday (2/21/19)
  2. Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
  3. Adial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adial’s AD04 for its Phase 3 Trial
  4. Adial Pharmaceuticals Submits Continuation Patent Application for Use of AD04 in Opioid Dependence and Abuse
  5. Adial Pharmaceuticals Appoints Leading Addiction Specialist to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder
  6. Dr. Bankole A. Johnson, Chairman of Adial Pharmaceuticals, Receives Prestigious American Society of Addiction Medicine Award
  7. Adial Pharmaceuticals CEO to Appear on CBS and Fox Affiliates to Discuss AD04 as a Potential Treatment for Alcohol and Opioid Use Disorder
  8. Adial Pharmaceuticals Receives $1.2 Million in Proceeds Through the Exercise of Warrants
  9. What Kind Of Investor Owns Most Of Adial Pharmaceuticals, Inc. (NASDAQ:ADIL)?
  10. Adial Pharmaceuticals Appoints Two Additional Global Thought Leaders to its Scientific Advisory Board to Advance AD04 and Combat Alcohol Use Disorder
  11. Bankole Johnson, MD and Chairman of the Board of Adial Pharmaceuticals Featured in Second Installment of The Doctors Channel Video Series
  12. Adial Pharmaceuticals to Present at The 2019 Wall Street Conference
  13. These 4 Healthcare Stocks Are Gaining Speed
  14. Why Adial Pharmaceuticals (ADIL) Stock Is Soaring Today
  15. 4 Healthcare Stocks Getting A Boost On Wednesday, Dec. 26, 2018
  16. Biotech News Driving These Companies
  17. Adial Pharmaceuticals Retires All Outstanding Debt
  18. Biotech Breakout Candidates
  19. Today's Research Reports on Trending Tickers: Aduro BioTech and Adial Pharmaceuticals
  20. Adial Pharmaceuticals Announces Amendment to License Agreement with the University of Virginia Licensing & Ventures Group